Jubilant Life Sciences gets USFDA nod for Bupropion Hydro chloride extended-release tablets

Mumbai, July 14, 2017: Pahrma Major, Jubilant Life Sciences today said its subsidiary has received an abbreviated new drug application (ANDA) final approval for Bupropion Hydro chloride extended-release tablets USP (XL), 150 mg and 300 mg. Bupropion Hydro chloride extended-release tablets, used for the treatment of major depressive disorder and prevention of seasonal effective disorder,company said in a filing with BSE. The approved product is the generic version of Well but rin XL of Valeant, which is used for the treatment of major depressive disorder and prevention of seasonal effective disorder. This is the fourth approval received by the company from the USFDA during the current financial year. As on March 31, 2017, Jubilant Life Sciences had 81 ANDAs for oral solids filed in the US, of which 51 have been approved, the filing added.